Co-Pay Programs: The CMS Best Price Revision

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 The Centers for Medicare and Medicaid Services (CMS) issued a Proposed Rule on June 19, 2020, that, if implemented as written, would present challenges to pharmaceutical manufacturers that offer co-pay assistance programs. The Proposed Rule addresses the impact that PBM co-pay accumulator adjustment programs have on co-pay assistance programs and their exclusion from the best price determination. As written in 42 CFR § 447.505(c)(8) through (12) - Determination of best price, manufacturer-sponsored co-pay assistance programs, coupons, [...]

Co-Pay Programs: The CMS Best Price Revision2021-01-16T14:17:04-05:00

Co-Pay Accumulators: Trends in 2020 & Beyond, PT. 2

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Earlier this week Rick Fry highlighted notable trends in co-pay accumulators thus far in 2020. As this issue continues, the natural question being asked by nearly everyone that has any involvement with the topic is “what’s next?” In this article, I’ll outline some specific areas of interest related to co-pay accumulators and maximizers heading into 2021. Clarity of New Rule Driving More Plans to Implement The 2020 Notice of Benefit and Payment Parameters caused uncertainty throughout [...]

Co-Pay Accumulators: Trends in 2020 & Beyond, PT. 22021-01-16T14:17:13-05:00

Co-Pay Accumulators: Trends in 2020 & Beyond

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Co-pay accumulators have become a fixture in the pharmaceutical patient support services landscape in recent years, as the ongoing tug-of-war between manufacturers and payers continues over who should bear the cost burden for specialty drugs. This week my colleague Jason Zemcik and I will be discussing the current state of co-pay accumulators. We will also examine recent market developments and share our expectations for the rest of this year and 2021. Today’s article will focus on [...]

Co-Pay Accumulators: Trends in 2020 & Beyond2021-01-16T14:17:48-05:00

Time Management in Clinical Trial Supplies

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 As those in the clinical trial arena know, the supply chain department is often charged with the difficult task of preparing clinical sites for their first patients under a very aggressive timeline. This process involves drug sourcing, label creation, packaging, shipping, and more. Clinical supply personnel understands how vital it is to solve problems, track down essential medications and supplies, manage budgets, and maintain important partner relationships. These responsibilities, if ignored, could threaten the success of [...]

Time Management in Clinical Trial Supplies2021-09-28T13:07:02-04:00

The 2021 Notice of Benefit and Payment Parameters: The Impact on Co-Pay Programs

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Last week, the Centers for Medicare and Medicaid Services (CMS) released the final 2021 Notice of Benefit and Payment Parameters (NBPP) rule. The complete rule is 350 pages and covers a variety of topics, including one that has been of particular interest to pharmaceutical manufacturers in recent years—co-pay accumulators. This post will provide a high-level overview of what the provisions in the 2021 NBPP mean for co-pay programs going forward. Plan sponsors can, but are not [...]

The 2021 Notice of Benefit and Payment Parameters: The Impact on Co-Pay Programs2021-01-16T14:19:11-05:00

Payer Intelligence: How Can It Be Combined With Technology to Enhance Patient Access?

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Scott Dulitz, Chief Strategy Officer at TrialCard, discusses how combining payer intelligence with market-leading technology can enhance patient access. TrialCard recently acquired Policy Reporter, a healthcare software solutions company that provides payer intelligence to the biopharmaceutical, medical device, and diagnostics industries. To learn more, schedule a demo of Policy Reporter or contact Scott (scott.dulitz@trialcard.com). The healthcare industry is entering an unprecedented era of medical innovation with several recent approvals for curative cell and gene therapies, novel digital therapeutics, [...]

Payer Intelligence: How Can It Be Combined With Technology to Enhance Patient Access?2021-01-16T14:19:20-05:00

Clinical Supply Availability & Speed to Study Start-Up

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 The Situation If you're part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it's simple doesn't mean it's easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. [...]

Clinical Supply Availability & Speed to Study Start-Up2021-09-27T13:35:59-04:00

COVID-19: A Message from President & CEO, Mark Bouck

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Over the past few weeks, all of us have been impacted by the COVID-19 pandemic. As we continue to adjust to these changing times, I wanted to update you on steps that TrialCard has taken to expand our business continuity plan. Our immediate goals are to (1) ensure the safety and well-being of our employees, (2) implement preventative measures to reduce the risk of exposure, and (3) continue to support our pharmaceutical manufacturers and their patients. We [...]

COVID-19: A Message from President & CEO, Mark Bouck2021-09-30T09:38:30-04:00

Rare is mighty. Rare is exceptional.

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Rare disease is defined as affecting fewer than 200,000 people. So, there is something about the term “rare disease”….when you hear that phrase….you think of that singular patient, that very particular and unique person. In fact, every day that I begin my work in the world of rare disease, I pause and reflect on that one patient that I may be fortunate enough to help. And sometimes, our perspective can shift in wonderful ways... In January, [...]

Rare is mighty. Rare is exceptional.2021-01-16T14:20:13-05:00

Co-Pay Card Fraud Detection: The Role of Processes and People

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 The issue of co-pay card fraud has been in the news for some time, but with the increased prevalence of high-priced specialty products, the cost of missing this fraud – literally – has become too high for manufacturers to rely only on traditional techniques, such as human investigators. This isn’t to say that there’s no role for people in stopping co-pay program fraud – they’re absolutely crucial!  They just can’t be the only tool used to [...]

Co-Pay Card Fraud Detection: The Role of Processes and People2021-01-16T14:20:30-05:00
Go to Top